Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 89.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 270,796 shares of the biopharmaceutical company’s stock after selling 2,217,004 shares during the period. Two Sigma Advisers LP’s holdings in Gilead Sciences were worth $25,013,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. Bridgewater Associates LP raised its stake in Gilead Sciences by 122.7% during the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company’s stock valued at $42,577,000 after acquiring an additional 253,994 shares during the last quarter. McAdam LLC increased its stake in shares of Gilead Sciences by 16.7% during the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock worth $2,344,000 after acquiring an additional 3,627 shares during the period. Nissay Asset Management Corp Japan ADV lifted its position in Gilead Sciences by 5.2% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company’s stock valued at $26,750,000 after purchasing an additional 14,009 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its holdings in Gilead Sciences by 3.9% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company’s stock valued at $13,132,000 after purchasing an additional 5,382 shares in the last quarter. Finally, Foster & Motley Inc. increased its position in Gilead Sciences by 80.4% during the 4th quarter. Foster & Motley Inc. now owns 10,587 shares of the biopharmaceutical company’s stock worth $978,000 after purchasing an additional 4,718 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. The Goldman Sachs Group raised their price target on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. Piper Sandler boosted their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Friday, April 25th. Royal Bank of Canada raised their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. Finally, Morgan Stanley upped their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $110.55.

Gilead Sciences Stock Up 2.8%

Shares of NASDAQ GILD opened at $109.11 on Wednesday. The firm has a market cap of $135.73 billion, a P/E ratio of 294.89, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The firm’s 50 day moving average price is $105.51 and its 200 day moving average price is $100.02.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business’s revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.32) EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.90%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences’s dividend payout ratio is currently 66.53%.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total value of $266,000.00. Following the transaction, the chief financial officer now directly owns 168,174 shares of the company’s stock, valued at approximately $17,893,713.60. This trade represents a 1.46% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 22,929 shares of company stock worth $2,634,220 in the last three months. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.